Central Idea
- Scientists have long sought medical treatments for Alzheimer’s disease but have faced limited success.
- The approval of the drug Lecanemab by the US FDA in 2023 has brought renewed optimism, as it shows promise in slowing the progression of Alzheimer’s in its early stages.
How brain cells die?
- Revealing the Connection: Researchers from Belgium and UK have shed light on the connection between abnormal proteins (amyloid and tau) and a process called necroptosis, which leads to cell death.
- Cell Death Mechanism: Necroptosis is a form of cell death typically triggered by immune responses to infection or inflammation, serving to eliminate damaged cells.
- Inflammatory Response: The study suggests that in Alzheimer’s patients, amyloid protein entering brain neurons triggers inflammation and alters the internal chemistry of the cells. Amyloid forms plaques, while tau forms tangles.
- MEG3 Molecule: When amyloid and tau processes occur simultaneously, brain cells produce a molecule called MEG3, which appears to be linked to cell death.
- Blocking MEG3: The researchers experimented by blocking the MEG3 molecule and found that brain cells survived when this molecule was inhibited.
- Experimental Approach: Human brain cells were transplanted into genetically modified mice that produced significant amyloid, allowing researchers to make these groundbreaking observations.
Hope for Alzheimer’s Treatment
- Historic Discovery: Researchers highlighted that this discovery marks the first time, after several decades of speculation, that scientists have found a plausible explanation for cell death in Alzheimer’s patients.
- Path to New Medicines: Some are optimistic that their findings will pave the way for new medical treatments targeting Alzheimer’s.
- Lecanemab’s Target: Lecanemab, a drug that specifically targets the amyloid protein, aligns with the potential to block the MEG3 molecule, offering the prospect of halting brain cell death in Alzheimer’s disease.
Understanding Brain’s Complex Processes
- Brain’s Enigma: The development of Alzheimer’s drugs has been hampered by a lack of understanding of the disease’s mechanisms within the brain.
- Amyloid and Tau: Amyloid and tau proteins are known to accumulate in the brain of Alzheimer’s patients, but their precise roles and how they contribute to cell death remained unclear.
Alzheimer’s Global Challenge
- Widespread Impact: Approximately 55 million people worldwide are affected by various forms of dementia, with Alzheimer’s being one of the prominent diseases.
- Disproportionate Burden: Two-thirds of dementia cases are found in developing countries, and with the aging global population, projections indicate that the number of dementia cases could reach 139 million by 2050, with China, India, Latin America, and Sub-Saharan Africa facing the greatest challenges.
